How much of Ionis Pharmaceuticals’ revenue comes from haram?

Ionis Pharmaceuticals earns its revenue from the following revenue sources:

  • Commercial Revenue:

Includes a range of products used to treat spinal muscular atrophy, polyneuropathy of hereditary transthyretin-mediated amyloidosis, and familial chylomicronemia syndrome.

  • Research and Development Revenue:

Generated from collaboration agreements for licensing and selling Ionis’s technology and manufacturing services.

The contributions from each of Ionis Pharmaceuticals’ revenue segments in their 2020 annual report were as follows:

Practical Islamic Finance concludes:

None of Ionis Pharmaceuticals’ revenue comes from anything inherently haram.

Does Ionis Pharmaceuticals rely on interest to operate?

Ionis Pharmaceuticals reports its Interest Income & Expenses as a net value.

According to the company’s annual report for the fiscal year ended December 31, 2020 (Numbers in thousands, U.S. dollars):

Interest Expense (net): $44,990

Total Expenses: $901,346

Interest Expense / Total Expense: 4.99%

The following table shows the declining percentage that net interest expense makes up relative to total expenses from 2018 to 2020.

201820192020
Interest Expense (net)6.78%6.44%4.99%
Ionis Pharmaceuticals’ use of interest over the years

Practical Islamic Finance concludes:

Riba is used but not relied upon in Ionis Pharmaceuticals’ operations.

What is Ionis Pharmaceuticals’ Environmental, Social, and Governance (ESG) impact?

Environment

No notable environmental highlights.

Social 

Ionis Pharmaceuticals has a relatively high Glassdoor rating of 3.8 out of 5.0 from over 60 current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.

In March 2021, Ionis Pharmaceuticals announced a grant program providing $50,000 in funding to researchers working to advance the understanding of transthyretin amyloidosis.

Governance

No notable governance highlights.

Practical Islamic Finance concludes:

Ionis Pharmaceuticals has a net positive ESG impact.

Comfort Rating

From Ionis Pharmaceuticals’ business, financial, and ESG reviews, Practical Islamic Finance rates Ionis Pharmaceuticals as:

Comfortable to invest in from a Halal perspective.

Sources

Glassdoor Reviews 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K Ionis Pharmaceuticals, Inc. 

FDA approves first drug for spinal muscular atrophy | FDA

Tegsedi (Inotersen Injection): Uses, Dosage, Side Effects, Interactions, Warning

Waylivra | European Medicines Agency